Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    IMUC   US4525361055

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
0.56(c) 0.5501(c) 0.525(c) 0.535(c) 0.5119(c) Last
549 849 624 074 1 449 805 808 646 640 657 Volume
-2.10% -1.77% -4.56% +1.90% -4.32% Change
More quotes
Financials ($)
Sales 2015 -
EBIT 2015 -14,7 M
Net income 2015 -14,6 M
Debt 2015 -
Yield 2015 -
Sales 2016 -
EBIT 2016 -19,8 M
Net income 2016 -19,8 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 0
Capi. / Sales 2016 0
Capitalization 46,2 M
More Financials
Company
ImmunoCellular Therapeutics Ltd. is a clinical-stage biotechnology company, which focuses on developing immune-based therapies for the treatment of brain and other cancers.Its cell-based vaccine technologies are primary platform technologies and commercial prospects will be heavily dependent on the... 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
03/25 IMMUNOCELLULAR THERAPEUTICS : Entry into a Material Definitive Agreement, Financ..
03/25 IMMUNOCELLULAR THERAPEUTICS : Establishes Manufacturing Agreement with PharmaCel..
03/19 IMMUNOCELLULAR THERAPEUTICS : Establishes Manufacturing Agreement with PharmaCel..
03/18 IMMUNOCELLULAR THERAPEUTICS : Announces Fourth Quarter and Full Year 2014 Financ..
03/15 IMMUNOCELLULAR THERAPEUTICS : Posts Fourth Quarter and Full Year 2014 Financial ..
03/15 IMMUNOCELLULAR THERAPEUTICS : Updates on 4Q and Full Year 2014 Financial Results
03/12 IMMUNOCELLULAR THERAPEUTICS : Releases Fourth Quarter and Full Year 2014 Financi..
03/10 IMMUNOCELLULAR THERAPEUTICS : Announces Fourth Quarter and Full Year 2014 Financ..
More news
Sector news : Biotechnology & Medical Research - NEC
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/12 ImmunoCellular's (IMUC) CEO Andrew Gengos on Q4 2014 Results - Earnings Call ..
03/10 CELLECTIS : Finding Value In A Crowded CAR-T Space
03/10 ImmunoCellular Therapeutics FY14 results
03/09 ImmunoCellular Therapeutics beats by $0.02
03/06 NEXT WEEK IN BIOTECH : Kythera Ad Comm, Roth Conference, Zogenix Earnings


Comments 
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | IMUC | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF